Particle.news

India Pharma Charts Shift From Generics to Biologics at CPHI & PMEC India

Regulators detailed streamlined approvals alongside fresh funding to accelerate R&D.

Overview

  • At the Greater Noida expo, CDSCO’s Dr. R. Chandrashekar said the move toward biosimilars, peptides, complex generics and next‑generation biologics is underway, supported by simplified approvals and decriminalisation of non‑serious offences.
  • He pointed to recommended pharma R&D projects of about ₹5,000 crore and the ₹1,00,000 crore Hospital Finance scheme as steps strengthening the research ecosystem.
  • Pharmexcil’s Namit Joshi urged a five‑year pivot to innovation and noted that companies are preparing launches in GLP‑1 class obesity drugs, indicating intensifying competition in high‑value segments.
  • Exports continue to grow but at a slower pace this year, with year‑to‑date gains reported at roughly 2.31% and ongoing concerns over potential US tariffs.
  • Speakers highlighted adoption of AI, machine learning and advanced biologic platforms and called for pharmacy curriculum updates to build an R&D‑ready workforce, as the expo drew over 2,000 exhibitors and 50,000 visitors.